These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29117576)

  • 1. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
    Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
    Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
    Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer.
    Anderson RA; Kelsey TW; Perdrix A; Olympios N; Duhamel O; Lambertini M; Clatot F
    Breast Cancer Res Treat; 2022 Apr; 192(2):273-282. PubMed ID: 34997365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
    Anderson RA; Cameron DA
    J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of Serum Anti-Mullerian Hormone in the Diagnosis of Ovarian Reserve Function in Patients with Premature Ovarian Insufficiency.
    Cai Y; Zhang Q; Yu K; Wang Q
    Biomed Res Int; 2022; 2022():3878359. PubMed ID: 36277874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
    Lee DY; Park YH; Lee JE; Choi D
    Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
    Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
    Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
    Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
    Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer.
    Chai J; Howie AF; Cameron DA; Anderson RA
    Eur J Cancer; 2014 Sep; 50(14):2367-74. PubMed ID: 25027307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
    Leonard RCF; Adamson DJA; Bertelli G; Mansi J; Yellowlees A; Dunlop J; Thomas GA; Coleman RE; Anderson RA;
    Ann Oncol; 2017 Aug; 28(8):1811-1816. PubMed ID: 28472240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
    Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
    Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review.
    Nelson SM; Davis SR; Kalantaridou S; Lumsden MA; Panay N; Anderson RA
    Hum Reprod Update; 2023 May; 29(3):327-346. PubMed ID: 36651193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very Low Levels of Serum Anti-Müllerian Hormone as a Possible Marker for Follicle Growth in Patients with Primary Ovarian Insufficiency Under Hormone Replacement Therapy.
    Kasahara Y; Osuka S; Bayasula ; Nakanishi N; Murase T; Nakamura T; Goto M; Kotani T; Iwase A; Kikkawa F
    Reprod Sci; 2021 Jan; 28(1):31-36. PubMed ID: 32737737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.
    Barnabei A; Strigari L; Marchetti P; Sini V; De Vecchis L; Corsello SM; Torino F
    Oncologist; 2015 Oct; 20(10):1111-8. PubMed ID: 26341758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
    Wang S; Pei L; Hu T; Jia M; Wang S
    Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of serum anti-mullerian hormone and inhibin B in prediction of ovarian response in patients with polycystic ovary syndrome.
    Zhang F; Liu XL; Rong N; Huang XW
    J Huazhong Univ Sci Technolog Med Sci; 2017 Feb; 37(1):70-73. PubMed ID: 28224431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of postchemotherapy ovarian function using markers of ovarian reserve.
    Henry NL; Xia R; Schott AF; McConnell D; Banerjee M; Hayes DF
    Oncologist; 2014 Jan; 19(1):68-74. PubMed ID: 24319018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian Reserve Markers in Premature Ovarian Insufficiency: Within Different Clinical Stages and Different Etiologies.
    Jiao X; Meng T; Zhai Y; Zhao L; Luo W; Liu P; Qin Y
    Front Endocrinol (Lausanne); 2021; 12():601752. PubMed ID: 33815272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.
    Visser JA; Schipper I; Laven JS; Themmen AP
    Nat Rev Endocrinol; 2012 Jan; 8(6):331-41. PubMed ID: 22231848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.